Movement Disorders [2010] 25 (7) : 927-931 (Hersh BP, Earl NL, Hauser RA, 
Stacy M.) Complete abstract 
Movement Disorders [2010] 25 (7) : 858-866 (Watts RL, Lyons KE, Pahwa R, Sethi 
K, Stern M, Hauser RA, Olanow W, Gray AM, Adams B, Earl NL; 228 Study 
Investigators) Complete abstract 
Prolonged Release Ropinirole was found to have a positive effect on 
Parkinson's Disease symptoms two weeks after its use begins. Prolonged Release 
Ropinirole is a once a day dopamine agonist that is marketed as Requip XL. For 
more information go to Ropinirole. However, the  improvements it caused were 
minimal. PR Ropinirole improved "off time" but only by 42 minutes per day.  It 
increased "on time" without dyskinesia, but only by 24 minutes per day. 
Improvements were seen in Parkinson's Disease scores, but only slightly. Even 
these small improvements are achieved by also causing side effects. 
In another study, Prolonged Release Ropinirole was found to delay the onset of 
dyskinesia when added to L-dopa when compared to increasing the L-dopa dosage. 
Otherwise there was no difference in Parkinson's Disease symptom scores. 
Adverse events were comparable in the two groups with nausea, dizziness, 
insomnia, back pain, arthralgia, somnolence, fatigue, and pain most commonly 
reported.  In order to refer to this article on its own

----------------------------------------------------------------------
To sign-off Parkinsn send a message to: mailto:[log in to unmask]
In the body of the message put: signoff parkinsn